Opinion|Videos|September 6, 2024
Key Factors to Consider when Switching to Biosimilars
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys discusses key factors to consider when switching to biosimilars.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- To what extent should the pharmacy team prioritize supporting the switch from a reference product to a biosimilar, and what factors should be considered in making this decision?
Advertisement
Related to this article
Convenience should not replace connection.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Community Pharmacists Guide Patients New to Glucose Monitoring
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5